1353 - Measurement of Calprotectin as a marker of bowel inflammation

Page last updated: 19 June 2018

Application Detail



Description of Medical Service

Faecal calprotectin is a marker for intestinal inflammation. Calprotectin concentration in faeces correlates with the severity of inflammation and is significantly increased in patients with bowel inflammation (IBD), but not elevated in patients with functional disorders like functional bowel disease (IBS). As a screening tool, faecal calprotectin tests reduce the need for invasive diagnostic procedures (such as colonoscopy), potentially leading to earlier diagnosis of IBD and IBS and subsequently improving patient management.

Description of Medical Condition

Patients present to a doctor with gastrointestinal symptoms suggestive of either organic (IBD) or functional (IBS) bowel disease, namely: chronic abdominal pain and discomfort; urgency and bloating; diarrhea; constipation; alternating bouts of diarrhea and constipation; and changes in bowel habits in the absence of alarm symptoms such as rectal bleeding or abnormal blood tests.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


Ratified Final Protocol

Ratified Final Protocol (Word 624 KB)
Ratified Final Protocol (PDF 1504 KB)

Assessment Report


Public Summary Document

Public Summary Document (Word 391 KB)
Public Summary Document (PDF 1319 KB)

Meetings for this Application


14 - 15 August 2014


8 - 9 February 2018


28 - 29 March 2018